サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428449

前臨床資産の世界市場レポート 2024

Preclinical Assets Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
前臨床資産の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

前臨床資産の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には9.3%の年間平均成長率（CAGR）で83億4,000万米ドルに成長すると予想されています。予測期間中に予想される成長は、精密医療と個別化療法の導入、人工知能（AI）と機械学習の統合、バイオバンキングの取り組みの拡大、希少疾患への注目の高まり、政府の取り組みと資金の増加に起因すると考えられます。予測期間中に予想される注目すべき動向には、高度なイメージング技術の出現、3Dオルガノイドモデルの利用、マルチオミクスデータの統合、強化された予測モデルの開発、自動化とハイスループットスクリーニングの増加が含まれます。

創薬への取り組みの拡大は、前臨床資産市場の成長軌道を推進する極めて重要な原動力となっています。創薬とは、医療用途に適した潜在的な化合物を特定する体系的なプロセスを指し、新しい治療薬を発見する最初の段階として機能します。 前臨床資産はこのドメイン内で重要な役割を果たし、その後の臨床開発に有望な分子を選択するために不可欠な重要なデータと証拠を提供します。たとえば、2022年1月の規制問題専門家協会の報告書は、2021年に米国食品医薬品局（FDA）によって承認された医薬品の約74％が少なくとも1つの迅速経路を利用しており、以前の68％から増加していることを強調しました。年。さらに、2023年6月に発表されたPharma IntelligenceのPharma R&D Annual Review 2022の洞察は、医薬品数が2020年の17,737から2022年には20,109に増加するなど、研究開発パイプラインの成長を示しています。したがって、急成長する創薬努力が前臨床資産市場の拡大を促進しています。

臨床試験の支出を軽減する必要性が高まっているため、前臨床資産市場の上昇の勢いが高まっています。臨床試験費用には、新しい医療介入の安全性、有効性、潜在的な利益を評価することを目的とした試験の計画、実施、管理にかかる総合的な費用が含まれます。これらの試験は、前臨床資産の安全性、有効性、および潜在的な副作用に関する重要な洞察を提供し、ヒト被験者における治療上の期待を検証します。たとえば、2023年 2月のGenetic Engineering and Biotechnology Newsから得られたデータは、世界のバイオ医薬品企業上位20社における新薬開発コストの大幅な上昇を浮き彫りにし、2022年の2億9,800万米ドルから2023年には約23億米ドルへと15%急増しました。増加額には、医薬品開発ライフサイクル全体、特に臨床試験段階で発生する費用が含まれます。したがって、臨床試験コストの削減が重視されるようになり、前臨床資産市場の拡大が促進されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の前臨床資産市場、サービス別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • 生物分析とDMPK（薬物代謝と薬物動態）研究
  • 毒性試験
  • 化合物の管理
  • 安全性薬理学
  • その他
  • 世界の前臨床資産市場、モデルタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 患者由来オルガノイド（PDO）モデル
  • 患者由来の異種移植片モデル
  • 世界の前臨床資産市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023、2023-2028年、2033年
  • バイオ医薬品企業
  • 政府機関
  • その他

第7章 地域および国の分析

  • 世界の前臨床資産市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の前臨床資産市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 前臨床資産市場の競合情勢
  • 前臨床資産市場の企業プロファイル
    • Laboratory Corporation of America
    • IQVIA Inc.
    • ICON PLC
    • Eurofins Scientific SE
    • PPD Inc.

第31章 その他の大手および革新的な企業

  • SGS SA
  • WuXi AppTec Co. Ltd.
  • Intertrek Group PLC
  • Charles River Laboratories International Inc.
  • Medpace Inc.
  • Pharmaron Beijing Co. Ltd.
  • Evotec SE
  • GenScript Biotech Corporation
  • Inotiv Inc.
  • SRI International Inc.
  • Shanghai Medicilon Inc.
  • Biocytogen Pharmaceuticals Beijing Co. Ltd.
  • AmplifyBio LLC
  • BioReliance Corporation
  • Pharmalegacy Laboratories Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14294

A preclinical asset encompasses all clinical trial supplies or equipment utilized during the preclinical development phase, bridging the gap between drug discovery in the laboratory and the commencement of human clinical trials. This preliminary stage involves essential feasibility assessments, iterative evaluations, and the gathering of safety data, primarily conducted on laboratory animals.

The primary categories of preclinical asset services include bioanalysis and DMPK (Drug Metabolism and Pharmacokinetic) studies, toxicology testing, compound management, safety pharmacology, and others. Bioanalysis and DMPK studies play a pivotal role in the drug development process, focusing on evaluating the pharmacokinetic and drug metabolism characteristics of potential new drugs. Various models, such as patient-derived organoid (PDO) models and patient-derived xenograft models, are employed by diverse end-users, including biopharmaceutical companies, government institutes, and others.

The preclinical assets market research report is one of a series of new reports from The Business Research Company that provides preclinical assets market statistics, including preclinical assets industry global market size, regional shares, competitors with a preclinical assets market share, detailed preclinical assets market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical assets industry. This preclinical assets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical assets market size has grown strongly in recent years. It will grow from $5.32 billion in 2023 to $5.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth observed in the historic period can be ascribed to the evolving needs in drug development, advancements in biotechnology, increasing regulatory requirements, growth in research funding, and collaborative efforts in research.

The preclinical assets market size is expected to see strong growth in the next few years. It will grow to $8.34 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine and personalized therapies, integration of artificial intelligence (AI) and machine learning, expansion of biobanking initiatives, a heightened focus on rare diseases, and increased government initiatives and funding. Notable trends expected in the forecast period include the emergence of advanced imaging techniques, utilization of 3D organoid models, integration of multi-omics data, development of enhanced predictive models, and increased automation and high-throughput screening.

The expansion of drug discovery efforts stands as a pivotal driver propelling the growth trajectory of the preclinical asset market. Drug discovery denotes the systematic process of identifying potential chemical compounds suitable for medicinal applications, serving as the initial phase in discovering new therapeutic drugs. Preclinical assets play a critical role within this domain, furnishing vital data and evidence essential for selecting promising molecules for subsequent clinical development. For instance, reports from the Regulatory Affairs Professionals Society in January 2022 highlighted that in 2021, approximately 74% of drugs approved by the US Food and Drug Administration (FDA) utilized at least one expedited pathway, marking an increase from 68% in the previous year. Additionally, insights from Pharma Intelligence's Pharma R&D Annual Review 2022 in June 2023 showcased growth in the R&D pipeline, with drug numbers rising from 17,737 in 2020 to 20,109 in 2022. Hence, the burgeoning drug discovery efforts fuel the expansion of the preclinical assets market.

The escalating need to mitigate clinical trial expenditures drives the upward momentum of the preclinical asset market. Clinical trial costs encompass the comprehensive expenses incurred in planning, executing, and managing trials aimed at assessing the safety, efficacy, and potential benefits of novel medical interventions. These trials provide critical insights into the safety, effectiveness, and potential side effects of preclinical assets, validating their therapeutic promise in human subjects. For instance, data sourced from Genetic Engineering and Biotechnology News in February 2023 underscored a substantial rise in the cost of developing new drugs among the top 20 global biopharma companies, soaring by 15% from $298 million in 2022 to approximately $2.3 billion in 2023. This increase encapsulates the expenses incurred throughout the drug development lifecycle, particularly in clinical trial phases. Hence, the mounting emphasis on reducing clinical trial costs propels the expansion of the preclinical asset market.

Product innovation has emerged as a significant trend driving growth within the preclinical assets market. Prominent players in this sector are heavily invested in pioneering new products and solutions to fortify their market position and gain a competitive edge. An illustrative case is the partnership between Charles River Laboratories International and Valo Health Inc. In April 2022, they introduced Logica, an AI-powered drug solution. This innovative offering seamlessly translates biological insights of clients into optimized preclinical assets. By amalgamating Charles River's extensive preclinical expertise with Valo's AI-driven Opal Computational Platform, Logica delivers a unified approach to drug discovery. This transformative partnership ensures the conversion of targets into candidate nominations, enhancing efficiency and yielding highly qualified leads for clients while aligning costs with value creation.

Strategic partnerships stand as a burgeoning trend shaping the landscape of the preclinical assets market. Leading entities operating in this domain are actively forging strategic alliances to bolster their market standing. An exemplar of this trend is the extended collaboration between AbbVie, a US-based pharmaceutical company, and Calibr, renowned for its prowess in research and drug development. This extended collaboration stems from the alliance between AbbVie and Scripps Research. Under this expanded partnership, Calibr is set to present AbbVie with new discovery targets and preclinical assets, aligning with mutual interests for potential options. This strategic collaboration enables both entities to continue advancing innovative preclinical and early-stage clinical assets, fostering an environment of growth and development within the market.

In October 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation based in the United States, completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for a total of $11.6 billion. Through this acquisition, Pfizer obtained access to a promising portfolio of calcitonin gene-related peptide (CGRP) receptor antagonists, which encompasses Rimegepant, Zavegepant, and a collection of preclinical CGRP assets. Biohaven Pharmaceutical Holding Company Ltd. is a clinical-stage biopharmaceutical company headquartered in the United States, known for its early-stage discovery program and various preclinical assets.

Major companies operating in the preclinical assets market report are Laboratory Corporation of America, IQVIA Inc., ICON PLC, Eurofins Scientific SE, PPD Inc., SGS SA, WuXi AppTec Co. Ltd., Intertrek Group PLC, Charles River Laboratories International Inc., Medpace Inc., Pharmaron Beijing Co. Ltd., Evotec SE, GenScript Biotech Corporation, Inotiv Inc., SRI International Inc., Shanghai Medicilon Inc., Biocytogen Pharmaceuticals Beijing Co. Ltd., AmplifyBio LLC, BioReliance Corporation, Pharmalegacy Laboratories Co. Ltd., Precigen Inc., ReproCELL Incorporated, InSphero AG, Crown Bioscience Inc., Comparative Biosciences Inc., TCG Lifesciences Pvt. Ltd., InVivo Biosystems, Pharmatest Services Ltd, Domainex Limited, Viroclinics Xplore

North America was the largest region in the preclinical assets market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical assets market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The preclinical assets market consists of revenues earned by entities by providing preclinical assets services such as process research and development, asymmetric synthesis, safety pharmacology, and custom synthesis. The market value includes the value of related goods sold by the service provider or included within the service offering. The preclinical assets market consists of sales of chemical compounds, biological samples, and sample storage systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical Assets Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preclinical assets market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for preclinical assets ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The preclinical assets market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies; Toxicology Testing; Compound Management; Safety Pharmacology; Other Services
  • 2) By Model Type: Patient Derived Organoid (PDO) Model; Patient Derived Xenograft Model
  • 3) By End User: Biopharmaceutical Companies; Government Institutes; Other End-Users
  • Companies Mentioned: Laboratory Corporation of America; IQVIA Inc.; ICON PLC; Eurofins Scientific SE; PPD Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Preclinical Assets Market Characteristics

3. Preclinical Assets Market Trends And Strategies

4. Preclinical Assets Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Preclinical Assets Market Size and Growth

  • 5.1. Global Preclinical Assets Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Preclinical Assets Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Preclinical Assets Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Preclinical Assets Market Segmentation

  • 6.1. Global Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Bioanalysis And DMPK (Drug Metabolism And Pharmacokinetic) Studies
  • Toxicology Testing
  • Compound Management
  • Safety Pharmacology
  • Other Services
  • 6.2. Global Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Patient Derived Organoid (PDO) Model
  • Patient Derived Xenograft Model
  • 6.3. Global Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Biopharmaceutical Companies
  • Government Institutes
  • Other End-Users

7. Preclinical Assets Market Regional And Country Analysis

  • 7.1. Global Preclinical Assets Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Preclinical Assets Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Preclinical Assets Market

  • 8.1. Asia-Pacific Preclinical Assets Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Preclinical Assets Market

  • 9.1. China Preclinical Assets Market Overview
  • 9.2. China Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Preclinical Assets Market

  • 10.1. India Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Preclinical Assets Market

  • 11.1. Japan Preclinical Assets Market Overview
  • 11.2. Japan Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Preclinical Assets Market

  • 12.1. Australia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Preclinical Assets Market

  • 13.1. Indonesia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Preclinical Assets Market

  • 14.1. South Korea Preclinical Assets Market Overview
  • 14.2. South Korea Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Preclinical Assets Market

  • 15.1. Western Europe Preclinical Assets Market Overview
  • 15.2. Western Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Preclinical Assets Market

  • 16.1. UK Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Preclinical Assets Market

  • 17.1. Germany Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Preclinical Assets Market

  • 18.1. France Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Preclinical Assets Market

  • 19.1. Italy Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Preclinical Assets Market

  • 20.1. Spain Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Preclinical Assets Market

  • 21.1. Eastern Europe Preclinical Assets Market Overview
  • 21.2. Eastern Europe Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Preclinical Assets Market

  • 22.1. Russia Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Preclinical Assets Market

  • 23.1. North America Preclinical Assets Market Overview
  • 23.2. North America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Preclinical Assets Market

  • 24.1. USA Preclinical Assets Market Overview
  • 24.2. USA Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Preclinical Assets Market

  • 25.1. Canada Preclinical Assets Market Overview
  • 25.2. Canada Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Preclinical Assets Market

  • 26.1. South America Preclinical Assets Market Overview
  • 26.2. South America Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Preclinical Assets Market

  • 27.1. Brazil Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Preclinical Assets Market

  • 28.1. Middle East Preclinical Assets Market Overview
  • 28.2. Middle East Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Preclinical Assets Market

  • 29.1. Africa Preclinical Assets Market Overview
  • 29.2. Africa Preclinical Assets Market, Segmentation By Service, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Preclinical Assets Market, Segmentation By Model Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Preclinical Assets Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Preclinical Assets Market Competitive Landscape And Company Profiles

  • 30.1. Preclinical Assets Market Competitive Landscape
  • 30.2. Preclinical Assets Market Company Profiles
    • 30.2.1. Laboratory Corporation of America
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. IQVIA Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. ICON PLC
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Eurofins Scientific SE
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. PPD Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Preclinical Assets Market Other Major And Innovative Companies

  • 31.1. SGS SA
  • 31.2. WuXi AppTec Co. Ltd.
  • 31.3. Intertrek Group PLC
  • 31.4. Charles River Laboratories International Inc.
  • 31.5. Medpace Inc.
  • 31.6. Pharmaron Beijing Co. Ltd.
  • 31.7. Evotec SE
  • 31.8. GenScript Biotech Corporation
  • 31.9. Inotiv Inc.
  • 31.10. SRI International Inc.
  • 31.11. Shanghai Medicilon Inc.
  • 31.12. Biocytogen Pharmaceuticals Beijing Co. Ltd.
  • 31.13. AmplifyBio LLC
  • 31.14. BioReliance Corporation
  • 31.15. Pharmalegacy Laboratories Co. Ltd.

32. Global Preclinical Assets Market Competitive Benchmarking

33. Global Preclinical Assets Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Preclinical Assets Market

35. Preclinical Assets Market Future Outlook and Potential Analysis

  • 35.1 Preclinical Assets Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Preclinical Assets Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Preclinical Assets Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer